ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Price-to-Free-Cash-Flow : N/A (As of Jun. 21, 2024)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Free-Cash-Flow?

As of today (2024-06-21), ImmuneOnco Biopharmaceuticals (Shanghai)'s share price is HK$14.48. ImmuneOnco Biopharmaceuticals (Shanghai)'s Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.08. Hence, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:01541's Price-to-Free-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 34.32
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.69. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$-1.08.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Free-Cash-Flow Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Free-Cash-Flow Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Free-Cash-Flow

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Free-Cash-Flow	-	-	-	-	-

Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow

For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow falls into.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Free-Cash-Flow Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio	=	Share Price	/	Free Cash Flow per Share (TTM)
	=	14.48	/	-1.083
	=	N/A

ImmuneOnco Biopharmaceuticals (Shanghai)'s Share Price of today is HK$14.48.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.08.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio

Market Cap

Free Cash Flow

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

ImmuneOnco Biopharmaceuticals (Shanghai) Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Price-to-Free-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines